Cincinnati, United States
Kurome Therapeutics, Inc. is a preclinical stage company based in the United States, with the slogan "A preclinical stage company focused on subverting cancer's ability to evade therapy." The company is focused on developing therapies that target cancer cells which have co-opted immune signaling pathways to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.
Founded in 2019, Kurome Therapeutics is pioneering the development of a series of IRAK1/4, panFLT3 inhibitors. The company's preclinical studies have demonstrated a broad range of efficacy in MDS and AML patient-derived cell lines, synergy with Venclexta® (Venetoclax) to improve potency, identification of a biomarker correlating with prognosis in AML patients, and maximal activation of immune signaling through this pathway in AML cells. Moreover, their research has shown increased overall survival in cell line and patient-derived xenograft models, maintenance of complete efficacy even in settings of adaptive resistance to FLT3 inhibitors and FLT3 mutations.
Kurome Therapeutics has attracted a significant $15.00M Series A investment on 10 June 2021, with participation from notable investors including CincyTech, Queen City Angels, Affinity Asset Advisors, and Medicxi Ventures.
The company's foundation lies in the research developed in the laboratory of Dr. Daniel Starczynowski at Cincinnati Children's Hospital Medical Center in collaboration with the National Center for Advancing Translational Sciences (NCATS) at the NIH.
Kurome Therapeutics holds promise in the field of biotechnology and healthcare with its innovative approach towards cancer therapy, backed by strong preclinical evidence and support from reputable investors.
